Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 20-28

  Hashimoto, Etsuko ^a   Tokushige, Katsutoshi ^a   Ludwig, Jurgen ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Classification; Clinical diagnosis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Pathological diagnosis; Steatohepatitis

Indexed keywords

ALCOHOL;

ALCOHOL CONSUMPTION; DISEASE CLASSIFICATION; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; INFLAMMATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER FATTY DEGENERATION; LIVER FIBROSIS; LIVER HISTOLOGY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW;

EID: 84920973863     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12333     Document Type: Review

References (93)

1. Kojima S, Watanabe N, Numata M etal. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38: 954-961.
2. Jimba S, Nakagami T, Takahashi M etal. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005; 22: 1141-1145.
3. Amarapurkar DN, Hashimoto E, Lesmana LA etal. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793.
4. Williams CD, Stengel J, Asike MI etal. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
5. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
6. Eguchi Y, Hyogo H, Ono M etal. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastrotenterol 2012; 47: 586-595.
7. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995; 9: 101-105.
8. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710-723.
9. Akahoshi M, Amasaki Y, Soda M etal. Correlation between fatty liver and coronary risk factors: apopulation study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001; 24: 337-343.
10. Donati G, Stagni B, Piscaglia F etal. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes:role of insulin resistance. Gut 2004; 53: 1020-1023.
11. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728.
12. Targher G, Bertolini L, Padovani R etal. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
13. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007; 22: 794-800.
14. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119.
15. Fu JF, Shi HB, Liu LR etal. Non-alcoholic fatty liver disease: an early mediator predicting metabolic syndrome in obese children? World J Gastroenterol 2011; 17: 735-742.
16. Siddiqui MS, Sterling RK, Luketic VA etal. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology 2013; 145: 1271-1279.
17. Yatsuji S, Hashimoto E, Tobari M etal. Influence of age and gender in Japanese patients with non-alcoholic steatohepatitis. Hepatol Res 2007; 37: 1034-1043.
18. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 (Suppl 1): 63-69.
19. Kogiso T, Hashimoto E, Tokushige K etal. Characteristics of gender differences and age in nonalcoholic steatohepatitis with regard to the complications of lifestyle-related disease, fat distribution, adipocytokines and SNPs. Kazo 2014; 55: 199-205.
20. Browning JD, Szczepaniak LS, Dobbins R etal. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethinicity. Hepatology 2004; 40: 1387-1395.
21. Kallwitz ER, Kumar M, Aggarwal R etal. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci 2008; 53: 1358-1363.
22. Palmer ND, Muani SK, Yerges-Armstrong LM etal. Characterization of European ancestory nonalcoholic fatty liver diseases-associated variants in individuals of African and Hispanic descent. Hepatology 2013; 58: 966-975.
23. Ludwig J, Viggiano TR, McGill DB etal. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
24. Teli MR, James OF, Burt AD etal. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22: 1714-1719.
25. Dam-Larsen S, Becker U, Franzmann MB etal. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009; 44: 1236-1243.
26. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
27. Ekstedt M, Franzén LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873.
28. Rafiq N, Bai C, Fang Y etal. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
29. Söderberg C, Stål P, Askling J etal. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
30. Sørensen HT, Mellemkjaer L, Jepsen P etal. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol 2003; 36: 356-359.
31. Evans CD, Oien KA, MacSween RN etal. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002; 55: 689-692.
32. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
33. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254.
34. Shimada M, Hashimoto E, Taniai M etal. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002; 37: 154-160.
35. Yasui K, Hashimoto E, Komorizono Y etal. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-433.
36. Yasui K, Hashimoto E, Tokushige K etal. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol Res 2012; 42: 767-773.
37. Tokushige K, Hashimoto E, Yatsuji S etal. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 2010; 45: 960-967.
38. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: growing evidence of an epidemic? Hepatol Res 2012; 42: 1-14.
39. Chalasani N, Yunossi Z, Lavine J etal. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
40. Ratziu V, Bellentani S, Cortez-Pinto H etal. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
41. Okanoue T, Saibara T, Ono M etal. The consensus Kobe 2009; Diagnosis and treatment of NASH. Kazo 2009; 50: 741-747. (In Japanese.)
42. Bellentani S, Saccoccio G, Costa G etal. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850.
43. Bellentani S, Saccoccio G, Masutti F etal. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000; 132: 112-117.
44. Sanyal AJ, Brunt EM, Kleiner DE etal. End points and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54: 344-353.
45. Ekstedt M, Franzen L, Holmqvist M etal. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic liver disease. Scand J Gastroenterol 2009; 44: 366-374.
46. Wechsler H, Austin SB. Binge drinking: the five/four measure. J Stud Alcohol 1998; 59: 122-124.
47. Barrio E, Tome S, Rodriguez I etal. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28: 131-136.
48. O'Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 2010; 51: 307-328.
49. Day CP, Bashir R, James OF etal. Investigation of the role of polymorphisms at the alcohol and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ damage. Hepatology 1991; 14: 798-801.
50. Monzoni A, Masutti F, Saccoccio G, Bellentani S, Tiribelli C, Giacca M. Genetic determinants of ethanol-induced liver damage. Mol Med 2001; 7: 255-262.
51. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011; 46: 1230-1237.
52. Tsutsumi M. The history of the diagnostic criteria for alcoholic liver disease and current status of alcoholic liver disease in Japan. Nihon Shokakibyo Gakkai Zasshi 2012; 109: 1509-1517. (In Japanese.)
53. Völzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol 2012; 21: 3492-3501.
54. Sookoian S, Castano GO, Pirola C. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43175 individuals. Gut 2013; 25: 1-2.
55. Dunn W, Sanyal AJ, Brunt EM etal. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57: 384-391.
56. Howard AA, Amsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus. Ann Intern Med 2004; 140: 211-219.
57. Ascha MS, Hanouneh IA, Lopez R etal. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
58. Taniai M, Hashimoto E, Tokushige K etal. Roles of gender, obesity, and lifestyle-related diseases in alcoholic liver disease: obesity does not influence the severity of alcoholic liver disease. Hepatol Res 2012; 42: 359-367.
59. Schaffner F. Non-alcoholic fatty liver. In: Berk JE, Haubrich WS, Kalser MH, eds. Bockus Gastroenterology, 4 edn. Philadelphia, PA: Saunders, 1985; 3049-3061.
60. Schaffner F, Thaler H. Nonalcoholic fatty liver diseases. Prog Liver Dis 1986; 8: 283-298.
61. Thayer WS. Inhibition of mitochondrial fatty acid oxidation in pentenoic acid-induced fatty liver. A possible model for Reye's syndrome. Biochem Pharmacol 1984; 33: 1187-1194.
62. Casteels-Van Daele M, Van Geet C, Wouters C, Eggermont E. Reye syndrome revisited: a descriptive term covering a group of heterogeneous disorders. Eur J Pediatr 2000; 159: 641-648.
63. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. Cell Biochem Funct 2008; 26: 741-746.
64. Zimmerman HJ. Drug-induced liver disease. In: Zimmerman HJ, ed. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 1999; 427-456.
65. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003; 7: 435-451.
66. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725.
67. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
68. Yoshioka Y, Hashimoto E, Yatsuji S etal. Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH. J Gastroenterol 2004; 39: 1215-1218.
69. Ponawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis. Hepatology 2000; 32: 689-691.
70. Ong J, Younossi ZM, Reddy V etal. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
71. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 2009; 15: 1843-1851.
72. Matteoni CA, Younossi ZM, Gramlich T etal. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
73. Brunt EM, Janney CG, DiBisceglie AM etal. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
74. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21: 3-16.
75. Kleiner DE, Brunt EM, Van Natta M etal. Nonalcoholic Steatohepatitis Clinical Research Network. Related Articles: design and validation of histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
76. Argo CK, Northup PG, Abdullah MS, Stephen H, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
77. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20: 594-598.
78. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
79. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-1109.
80. Ratziu V, Giral P, Charlotte F etal. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.
81. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047.
82. Fassio E, Alvarez E, Dom'inguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826.
83. Hui AY, Wong VW, Chan HL etal. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005; 21: 407-413.
84. Schwimmer JB, Behling C, Newbury R etal. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-649.
85. Nobili V, Manco M, Ciampalini P etal. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. Eur J Endocrinol 2006; 155: 735-743.
86. Patton HM, Lavine JE, Van Natta ML etal. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1961-1971.
87. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40: 475-483.
88. Brunt EM, Kleiner DE, Wilson LA etal. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53: 810-820.
89. International Group. Acute and chronic hepatitis revisited. Review by an international group. Lancet 1977; 29 (2): 914-919.
90. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC Groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832.
91. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 3-8.
92. Ikeda K, Saitoh S, Suzuki Y etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-938.
93. Younossi ZM, Stepanova M, Rafiq N etal. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-1882.